These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16260906)

  • 21. Mortality and progression to AIDS after starting highly active antiretroviral therapy.
    van Sighem AI; van de Wiel MA; Ghani AC; Jambroes M; Reiss P; Gyssens IC; Brinkman K; Lange JM; de Wolf F;
    AIDS; 2003 Oct; 17(15):2227-36. PubMed ID: 14523280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level.
    Viard JP; Burgard M; Hubert JB; Aaron L; Rabian C; Pertuiset N; Lourenço M; Rothschild C; Rouzioux C
    AIDS; 2004 Jan; 18(1):45-9. PubMed ID: 15090828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamics of T-cell subsets and their relationship with oral and systemic opportunistic infections in HIV/AIDS patients during the first year of HAART in Guangxi, China.
    Zhang L; Huang Y; Liu Z; Liu W; Qin Q; Tao R
    J Med Virol; 2015 Jul; 87(7):1158-67. PubMed ID: 25777553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era.
    Vilchez RA; Finch CJ; Jorgensen JL; Butel JS
    Medicine (Baltimore); 2003 Mar; 82(2):77-81. PubMed ID: 12640183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrush and fever as markers of immune competence in the era of highly active antiretroviral therapy.
    Skolasky RL; Phair J; Detels R; Riddler S; Margolick J; Jacobson LP
    AIDS Res Hum Retroviruses; 2001 Sep; 17(14):1311-6. PubMed ID: 11602040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
    Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
    J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART.
    Lapadula G; Chatenoud L; Gori A; Castelli F; Di Giambenedetto S; Fabbiani M; Maggiolo F; Focà E; Ladisa N; Sighinolfi L; Di Pietro M; Pan A; Torti C;
    PLoS One; 2015; 10(5):e0124741. PubMed ID: 26020949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis.
    Bogaards JA; Weverling GJ; Geskus RB; Miedema F; Lange JM; Bossuyt PM; Goudsmit J
    Antivir Ther; 2003 Feb; 8(1):43-50. PubMed ID: 12713063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.
    Mocroft A; Devereux H; Kinloch-de-Loes S; Wilson D; Madge S; Youle M; Tyrer M; Loveday C; Phillips AN; Johnson MA
    AIDS; 2000 Jul; 14(11):1545-52. PubMed ID: 10983641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.
    Miller V; Sabin CA; Phillips AN; Rottmann C; Rabenau H; Weidmann E; Rickerts V; Findhammer S; Helm EB; Staszewski S
    AIDS; 2000 Sep; 14(14):2129-36. PubMed ID: 11061654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA.
    Cu-Uvin S; Caliendo AM; Reinert S; Chang A; Juliano-Remollino C; Flanigan TP; Mayer KH; Carpenter CC
    AIDS; 2000 Mar; 14(4):415-21. PubMed ID: 10770544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AIDS update 1999: viral reservoirs and immune-based therapies.
    Isada CM; Calabrese LH
    Cleve Clin J Med; 1999 May; 66(5):267-9. PubMed ID: 10330777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients.
    McCutchan JA; Wu JW; Robertson K; Koletar SL; Ellis RJ; Cohn S; Taylor M; Woods S; Heaton R; Currier J; Williams PL
    AIDS; 2007 May; 21(9):1109-17. PubMed ID: 17502721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy.
    Mönkemüller KE; Call SA; Lazenby AJ; Wilcox CM
    Am J Gastroenterol; 2000 Feb; 95(2):457-62. PubMed ID: 10685750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of AIDS-defining events among advanced naïve patients after HAART.
    Torti C; Lapadula G; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Pietro MD; Migliorino G; Quiros-Roldan E; Ladisa N; Sighinolfi L; Gatti F; Carosi G;
    HIV Clin Trials; 2007; 8(3):112-20. PubMed ID: 17621458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.
    MacArthur RD; Perez G; Walmsley S; Baxter JD; Mullin CM; Neaton JD; ;
    HIV Clin Trials; 2005; 6(3):127-35. PubMed ID: 16192247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/microL): an analysis of 338 clinical events from a randomized clinical trial.
    Floridia M; Fragola V; Galluzzo CM; Giannini G; Pirillo MF; Andreotti M; Tomino C; Vella S
    HIV Med; 2002 Apr; 3(2):75-84. PubMed ID: 12010353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
    Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
    AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor.
    Calista D; Morri M; Stagno A; Boschini A
    Am J Clin Dermatol; 2002; 3(1):59-62. PubMed ID: 11817969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.